Latest News

Both apixaban and rivaroxaban resulted in improved risk of stroke, systemic embolism, major bleeding, and cardiovascular death compared to no anticoagulation.

SURPASS-CVOT showed tirzepatide is non-inferior to dulaglutide for cardiovascular events in more than 13,000 adults with type 2 diabetes.

The ESC, ACC, AHA, and WHF jointly replaced numerical MI typing with primary, secondary, and procedure-related categories, announced at ESC Congress 2026.

CARDIO-TTRansform data presented at ESC 2026 showed no significant reduction in cardiovascular mortality or recurrent events with eplontersen versus placebo in ATTR-CM.

The approval adds brepocitinib (Lisraya), an oral JAK/TYK2 inhibitor, as the first agent specifically studied and approved for dermatomyositis in adults.

Brendan Neuen, MBBS, PhD, joins Shikha Wadhwani, MD, MS, to unpack FIND-CKD's GN subgroup data and 23% risk reduction.

Mahboobeh Mahdavinia, MD, PhD, discusses new FORWARD data showing peanut and shellfish allergies resolve far less often than milk, soy, or wheat.

LEADderm 2026 brings dermatology leaders to Newport Beach, California, August 29-30, for sessions on leadership, AI in education, and career growth.

The Phase 3 CROSSING trial showed tezepelumab improved histologic remission and dysphagia symptoms through week 52 in eosinophilic esophagitis.

Baseline structural damage accounted for most of the variance in placebo-arm radiographic progression across 6 PsA trials.

In this episode of Diabetes Dialogue, co-hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Casey Halpern, MD, to discuss SynchNeuro's investigational, non-invasive EEG-based glucose monitor.

IMPACT-PLuS investigator Jennifer A. Dantzer says predictive biomarkers and formal remission testing remain unanswered questions in peanut OIT.

In this episode, co-hosts Isaacs and Bellini are joined by Eden Miller, DO, and Davida Kruger, NP, to discuss the FDA's recent clearance of the FreeStyle Libre Duo ketone monitor.

Daraxonrasib (Rasonque) extended median survival to 13.2 months versus 6.7 months with chemotherapy in a phase 3 trial.

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and building patient trust and adherence.

Saakshi Khattri, MD, discusses mental health screening gaps in psoriasis and a new Th17/type 2 immune signature study pointing toward personalized care.

Saakshi Khattri, MD, discusses oral TYK2 inhibitor and IL-23 antagonist data alongside weight-loss combination therapy reshaping psoriasis and PsA care.

Rethinking IgA Nephropathy Risk and Treatment, With Ali Mehdi, MD, MEd

Abbott's Libre Duo 10 Day earned FDA De Novo authorization, becoming the first continuous dual glucose-ketone monitor for diabetes.

Nipocalimab-aahu (IMAAVY) is now approved for wAIHA, based on Phase 2/3 ENERGY trial data showing durable hemoglobin response.

In this segment of his Q&A interview, Charles Lynde, MD, reviews upadacitinib's safety profile in the UP-AA trials and how it could reshape alopecia areata care.

In this Q&A, Charles Lynde, MD, highlighted upadacitinib's impact on severe alopecia areata in new phase 3 data addressing the hair loss condition.

This episode discusses the recent results from trials of IcoSema and a new highly concentrated insulin aspart.